Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


Articles published in Cancer Res

Retrieve available abstracts of 101 articles:
HTML format
Text format



Single Articles


    May 2018
  1. LU X, Pan X, Wu CJ, Zhao D, et al
    An in vivo screen identifies PYGO2 as a driver for metastatic prostate cancer.
    Cancer Res. 2018 May 16. pii: 0008-5472.CAN-17-3564.
    PubMed     Text format     Abstract available


  2. MOSES MA, Kim YS, Rivera-Marquez GM, Oshima N, et al
    Targeting the Hsp40/Hsp70 chaperone axis as a novel strategy to treat castration-resistant prostate cancer.
    Cancer Res. 2018 May 15. pii: 0008-5472.CAN-17-3728.
    PubMed     Text format     Abstract available


    April 2018
  3. ZHANG Z, Cheng L, Li J, Farah E, et al
    Inhibition of the Wnt/beta-catenin pathway overcomes resistance to enzalutamide in castration-resistant prostate cancer.
    Cancer Res. 2018 Apr 26. pii: 0008-5472.CAN-17-3006.
    PubMed     Text format     Abstract available


    March 2018
  4. DAS SK, Pradhan AK, Bhoopathi P, Talukdar S, et al
    The MDA-9/Syntenin/IGF-1R/STAT3 axis directs prostate cancer invasion.
    Cancer Res. 2018 Mar 23. pii: 0008-5472.CAN-17-2992.
    PubMed     Text format     Abstract available


  5. YU G, Cheng CJ, Lin SC, Lee YC, et al
    Organelle-derived acetyl-CoA promotes prostate cancer cell survival, migration, and metastasis via activation of calmodulin kinase II.
    Cancer Res. 2018 Mar 13. pii: 0008-5472.CAN-17-2392.
    PubMed     Text format     Abstract available


  6. YU-LEE LY, Yu G, Lee YC, Lin SC, et al
    Osteoblast-secreted factors mediate dormancy of metastatic prostate cancer in the bone via activation of the TGFbetaRIII-p38MAPK-pS249/T252RB pathway.
    Cancer Res. 2018 Mar 7. pii: 0008-5472.CAN-17-1051.
    PubMed     Text format     Abstract available


    February 2018
  7. CI X, Hao J, Dong X, Choi SYC, et al
    Heterochromatin protein 1alpha mediates development and aggressiveness of neuroendocrine prostate cancer.
    Cancer Res. 2018 Feb 27. pii: 0008-5472.CAN-17-3677.
    PubMed     Text format     Abstract available


  8. SORRENTINO C, Ciummo SL, Cipollone G, Caputo S, et al
    Interleukin-30/IL-27p28 shapes prostate cancer stem-like cell behavior and is critical for tumor onset and metastasization.
    Cancer Res. 2018 Feb 27. pii: 0008-5472.CAN-17-3117.
    PubMed     Text format     Abstract available


  9. LACHANCE J, Berens AJ, Hansen MEB, Teng AK, et al
    Genetic hitchhiking and population bottlenecks contribute to prostate cancer disparities in men of African descent.
    Cancer Res. 2018 Feb 8. pii: 0008-5472.CAN-17-1550.
    PubMed     Text format     Abstract available


  10. XIAO L, Wang Y, Xu K, Hu H, et al
    Nuclear receptor LRH-1 functions to promote castration-resistant growth of prostate cancer via its promotion of intratumoral androgen biosynthesis.
    Cancer Res. 2018 Feb 8. pii: 0008-5472.CAN-17-2341.
    PubMed     Text format     Abstract available


  11. JUNG Y, Cackowski FC, Yumoto K, Decker A, et al
    CXCL12gamma Promotes Development of Metastatic Castration Resistant Prostate Cancer by Induction of Cancer Stem Cell and Neuroendocrine Phenotypes.
    Cancer Res. 2018 Feb 5. pii: 0008-5472.CAN-17-2332.
    PubMed     Text format     Abstract available


  12. BHAGIRATH D, Yang TL, Bucay N, Sekhon K, et al
    MicroRNA-1246 is an exosomal biomarker for aggressive prostate cancer.
    Cancer Res. 2018 Feb 1. pii: 0008-5472.CAN-17-2069.
    PubMed     Text format     Abstract available


    January 2018
  13. MCCLINCH K, A Avelar R, Callejas D, Izadmehr S, et al
    Small molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer.
    Cancer Res. 2018 Jan 22. pii: 0008-5472.CAN-17-0123.
    PubMed     Text format     Abstract available


    December 2017
  14. COUTURE F, Sabbagh R, Kwiatkowska A, Desjardins R, et al
    PACE4 Undergoes an Oncogenic Alternative Splicing Switch in Cancer.
    Cancer Res. 2017;77:6863-6879.
    PubMed     Text format     Abstract available


  15. HORNING AM, Wang Y, Lin CK, Louie AD, et al
    Single-cell RNA-seq reveals a subpopulation of prostate cancer cells with enhanced cell cycle-related transcription and attenuated androgen response.
    Cancer Res. 2017 Dec 12. pii: 0008-5472.CAN-17-1924.
    PubMed     Text format     Abstract available


  16. YOU S, Freeman MR
    A Systems Approach to Prostate Cancer Classification-Response.
    Cancer Res. 2017 Dec 6. pii: 0008-5472.CAN-17-0239.
    PubMed     Text format    


  17. THYSELL E, Ylitalo EB, Jernberg E, Bergh A, et al
    A Systems Approach to Prostate Cancer Classification-Letter.
    Cancer Res. 2017 Dec 6. pii: 0008-5472.CAN-16-3231.
    PubMed     Text format    


  18. YANG Y, Blee AM, Wang D, An J, et al
    Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion.
    Cancer Res. 2017;77:6524-6537.
    PubMed     Text format     Abstract available


    November 2017
  19. MARTIN-MARTIN N, Zabala-Letona A, Fernandez-Ruiz S, Arreal L, et al
    PPARdelta elicits ligand-independent repression of Trefoil Factor Family to limit prostate cancer growth.
    Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0908.
    PubMed     Text format     Abstract available


  20. EMERSON MA, Banegas MP, Chawla N, Achacoso N, et al
    Disparities in Prostate, Lung, Breast, and Colorectal Cancer Survival and Comorbidity Status among Urban American Indians and Alaskan Natives.
    Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0429.
    PubMed     Text format     Abstract available


  21. ALEXANDER J, Kendall J, McIndoo J, Rodgers L, et al
    Utility of single cell genomics in diagnostic evaluation of prostate cancer.
    Cancer Res. 2017 Nov 27. pii: 0008-5472.CAN-17-1138.
    PubMed     Text format     Abstract available


  22. MURPHY SJ, Kosari F, Karnes RJ, Nasir A, et al
    Retention of Interstitial Genes between TMPRSS2 and ERG Is Associated with Low-Risk Prostate Cancer.
    Cancer Res. 2017;77:6157-6167.
    PubMed     Text format     Abstract available


    October 2017
  23. KIM S, Alsaidan OA, Goodwin O, Li Q, et al
    Blocking myristoylation of Src inhibits its kinase activity and suppresses prostate cancer progression.
    Cancer Res. 2017 Oct 16. pii: canres.0981.2017.
    PubMed     Text format     Abstract available


  24. PONNUSAMY S, Coss CC, Thiyagarajan T, Watts K, et al
    Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer.
    Cancer Res. 2017 Oct 4. pii: canres.0976.2017.
    PubMed     Text format     Abstract available


  25. DAMASCHKE NA, Yang B, Bhusari S, Avilla M, et al
    Loss of Igf2 Gene Imprinting in Murine Prostate Promotes Widespread Neoplastic Growth.
    Cancer Res. 2017;77:5236-5247.
    PubMed     Text format     Abstract available


    September 2017
  26. SAN MARTIN R, Pathak R, Jain A, Jung SY, et al
    Tenascin-C and integrin alpha9 mediate interactions of prostate cancer with the bone microenvironment.
    Cancer Res. 2017 Sep 15. pii: canres.0064.2017.
    PubMed     Text format     Abstract available


  27. LIANG Y, Ahmed M, Guo H, Soares F, et al
    LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression.
    Cancer Res. 2017 Sep 15. pii: canres.0496.2017.
    PubMed     Text format     Abstract available


    August 2017
  28. WANG L, Song G, Zhang X, Feng T, et al
    PADI2-mediated citrullination promotes prostate cancer progression.
    Cancer Res. 2017 Aug 17. pii: canres.0150.2017.
    PubMed     Text format     Abstract available


  29. JIN L, Garcia J, Chan E, de la Cruz C, et al
    Therapeutic targeting of the CBP/p300 bromodomain blocks the growth of castration-resistant prostate cancer.
    Cancer Res. 2017 Aug 17. pii: canres.0314.2017.
    PubMed     Text format     Abstract available


  30. SCHER HI, Graf RP, Schreiber N, McLaughlin B, et al
    Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer.
    Cancer Res. 2017 Aug 17. pii: canres.1353.2017.
    PubMed     Text format     Abstract available


  31. VAN ETTEN JL, Nyquist M, Li Y, Yang R, et al
    Targeting a single alternative polyadenylation site coordinately blocks expression of androgen receptor mRNA splice variants in prostate cancer.
    Cancer Res. 2017 Aug 15. pii: canres.0320.2017.
    PubMed     Text format     Abstract available


  32. VAN ETTEN JL, Nyquist M, Li Y, Yang R, et al
    Targeting a Single Alternative Polyadenylation Site Coordinately Blocks Expression of Androgen Receptor mRNA Splice Variants in Prostate Cancer.
    Cancer Res. 2017 Aug 15. doi: 10.1158/0008-5472.CAN-17-0320.
    PubMed     Text format     Abstract available


  33. BAINOR AJ, Deng FM, Wang Y, Lee P, et al
    Chromatin-associated protein SIN3B prevents prostate cancer progression by inducing senescence.
    Cancer Res. 2017 Aug 14. pii: canres.3410.2016.
    PubMed     Text format     Abstract available


    July 2017
  34. YIN Y, Li R, Xu K, Ding S, et al
    Androgen receptor variants mediate DNA repair after prostate cancer irradiation.
    Cancer Res. 2017 Jul 28. pii: canres.0164.2017.
    PubMed     Text format     Abstract available



  35. Correction: MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer.
    Cancer Res. 2017;77:3961.
    PubMed     Text format    


  36. SAHA A, Ahn S, Blando J, Su F, et al
    Proinflammatory CXCL12-CXCR4/CXCR7 signaling axis drives Myc-induced prostate cancer in obese mice.
    Cancer Res. 2017 Jul 7. pii: canres.0284.2017.
    PubMed     Text format     Abstract available


    June 2017
  37. LOVERIDGE CJ, Mui EJ, Patel R, Tan EH, et al
    Increased T-cell Infiltration Elicited by Erk5 Deletion in a Pten-Deficient Mouse Model of Prostate Carcinogenesis.
    Cancer Res. 2017;77:3158-3168.
    PubMed     Text format     Abstract available


  38. WANG Y, Wang J, Zhang L, Karatas OF, et al
    RGS12 is a novel tumor suppressor gene in African American prostate cancer that represses AKT and MNX1 expression.
    Cancer Res. 2017 Jun 13. pii: canres.0669.2017.
    PubMed     Text format     Abstract available


    May 2017

  39. Correction: Metastatic Progression of Prostate Cancer Is Mediated by Autonomous Binding of Galectin-4-O-Glycan to Cancer Cells.
    Cancer Res. 2017;77:2772.
    PubMed     Text format    


  40. MALEK R, Gajula RP, Williams RD, Nghiem B, et al
    TWIST1-WDR5-Hottip regulates Hoxa9 chromatin to facilitate prostate cancer metastasis.
    Cancer Res. 2017 May 8. pii: canres.2797.2016.
    PubMed     Text format     Abstract available


  41. PALTOGLOU S, Das R, Townley SL, Hickey T, et al
    Novel androgen receptor co-regulator GRHL2 exerts both oncogenic and anti-metastatic functions in prostate cancer.
    Cancer Res. 2017 May 4. pii: canres.1616.2016.
    PubMed     Text format     Abstract available


  42. IBRAHIM-HASHIM A, Robertson-Tessi M, Enriquez-Navas PM, Damaghi M, et al
    Defining Cancer Subpopulations by Adaptive Strategies Rather Than Molecular Properties Provides Novel Insights into Intratumoral Evolution.
    Cancer Res. 2017;77:2242-2254.
    PubMed     Text format     Abstract available


    April 2017
  43. KOLONIN MG, Sergeeva A, Staquicini DI, Smith TL, et al
    Interaction between tumor cell surface receptor RAGE and proteinase 3 mediates prostate cancer metastasis to bone.
    Cancer Res. 2017 Apr 20. pii: canres.0708.2016.
    PubMed     Text format     Abstract available


  44. WEN D, Peng Y, Lin F, Singh RK, et al
    Micellar delivery of miR-34a modulator rubone and paclitaxel in resistant prostate cancer.
    Cancer Res. 2017 Apr 20. pii: canres.2355.2016.
    PubMed     Text format     Abstract available


  45. CHEN HY, Larson PEZ, Bok RA, von Morze C, et al
    Assessing Prostate Cancer Aggressiveness with Hyperpolarized Dual-Agent 3D Dynamic Imaging of Metabolism and Perfusion.
    Cancer Res. 2017 Apr 20. pii: canres.2083.2016.
    PubMed     Text format     Abstract available


    March 2017
  46. KURMIS AA, Yang F, Welch TR, Nickols NG, et al
    A pyrrole-imidazole polyamide is active against enzalutamide-resistant prostate cancer.
    Cancer Res. 2017 Mar 30. pii: canres.2503.2016.
    PubMed     Text format     Abstract available


  47. MIAO L, Yang L, Li R, Nava Rodrigues D, et al
    Disrupting androgen receptor signaling induces Snail-mediated epithelial-mesenchymal plasticity in prostate cancer.
    Cancer Res. 2017 Mar 16. pii: canres.2169.2016.
    PubMed     Text format     Abstract available


  48. WEI X, Xu Y, Xu FF, Chaiswing L, et al
    RelB Expression Determines the Differential Effects of Ascorbic Acid in Normal and Cancer Cells.
    Cancer Res. 2017;77:1345-1356.
    PubMed     Text format     Abstract available


  49. OH DY, Cham J, Zhang L, Fong G, et al
    Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire.
    Cancer Res. 2017;77:1322-1330.
    PubMed     Text format     Abstract available


    February 2017
  50. THOMAS JD, Longen CG, Oyer HM, Chen N, et al
    Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer.
    Cancer Res. 2017 Feb 24. pii: canres.1055.2016.
    PubMed     Text format     Abstract available


  51. ZHANG K, Guo Y, Wang X, Zhao H, et al
    WNT/beta-catenin directs self-renewal symmetric cell division of hTERThigh prostate cancer stem cells.
    Cancer Res. 2017 Feb 16. pii: canres.1887.2016.
    PubMed     Text format     Abstract available


  52. MINCIACCHI VR, Spinelli C, Reis-Sobreiro M, Cavallini L, et al
    MYC mediates large oncosome-induced fibroblast reprogramming in prostate cancer.
    Cancer Res. 2017 Feb 15. pii: canres.2942.2016.
    PubMed     Text format     Abstract available


  53. MANZO T, Sturmheit T, Basso V, Petrozziello E, et al
    T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFalpha Expression and Empower Adoptive Cell Therapy for Solid Tumors.
    Cancer Res. 2017;77:658-671.
    PubMed     Text format     Abstract available


    January 2017
  54. ALFAQIH MA, Nelson ER, Liu W, Safi R, et al
    CYP27A1 loss dysregulates cholesterol homeostasis in prostate cancer.
    Cancer Res. 2017 Jan 27. pii: canres.2738.2016.
    PubMed     Text format     Abstract available


  55. VAN OORSCHOT B, Uitterhoeve L, Oomen I, Ten Cate R, et al
    Prostate cancer patients with late radiation toxicity exhibit reduced expression of genes involved in DNA double strand break repair and homologous recombination.
    Cancer Res. 2017 Jan 20. pii: canres.1966.2016.
    PubMed     Text format     Abstract available


  56. NANDANA S, Tripathi M, Duan P, Chu CY, et al
    Bone metastasis of prostate cancer can be therapeutically targeted at the TBX2-WNT signaling axis.
    Cancer Res. 2017 Jan 20. pii: canres.0497.2016.
    PubMed     Text format     Abstract available


  57. BERNICHTEIN S, Pigat N, Barry Delongchamps N, Boutillon F, et al
    Vitamin D3 Prevents Calcium-Induced Progression of Early-Stage Prostate Tumors by Counteracting TRPC6 and Calcium Sensing Receptor Upregulation.
    Cancer Res. 2017;77:355-365.
    PubMed     Text format     Abstract available


    December 2016
  58. DAS R, Gregory PA, Fernandes RC, Denis I, et al
    MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2.
    Cancer Res. 2016 Dec 23. pii: canres.2529.2016.
    PubMed     Text format     Abstract available


  59. THANGAVEL C, Boopathi E, Liu Y, Haber A, et al
    RB loss promotes prostate cancer metastasis.
    Cancer Res. 2016 Dec 6. pii: canres.1589.2016.
    PubMed     Text format     Abstract available


    November 2016
  60. CHOUDHURY AD, Schinzel AC, Cotter MB, Lis RT, et al
    Castration resistance in prostate cancer is mediated by the kinase NEK6.
    Cancer Res. 2016 Nov 29. pii: canres.0455.2016.
    PubMed     Text format     Abstract available


  61. AUDET-WALSH E, Yee T, McGuirk S, Vernier M, et al
    Androgen-dependent repression of ERRgamma reprograms metabolism in prostate cancer.
    Cancer Res. 2016 Nov 7. pii: canres.1204.2016.
    PubMed     Text format     Abstract available


  62. FONG KW, Zhao JC, Kim J, Li S, et al
    Polycomb-mediated disruption of an androgen receptor feedback loop drives castration-resistant prostate cancer.
    Cancer Res. 2016 Nov 4. pii: canres.1949.2016.
    PubMed     Text format     Abstract available


  63. GELMAN IH
    How the TRAMP Model Revolutionized the Study of Prostate Cancer Progression.
    Cancer Res. 2016;76:6137-6139.
    PubMed     Text format    


    October 2016
  64. DAY KC, Lorenzatti Hiles G, Kozminsky M, Dawsey SJ, et al
    HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone.
    Cancer Res. 2016 Oct 28. pii: canres.1656.2016.
    PubMed     Text format     Abstract available


    September 2016
  65. VARZAVAND A, Hacker W, Ma D, Gibson-Corley KN, et al
    alpha3beta1 Integrin suppresses prostate cancer metastasis via regulation of the Hippo pathway.
    Cancer Res. 2016 Sep 28. pii: canres.1483.2016.
    PubMed     Text format     Abstract available


  66. XIE M, Vesuna F, Tantravedi S, Bol GM, et al
    RK-33 radiosensitizes prostate cancer cells by blocking the RNA helicase DDX3.
    Cancer Res. 2016 Sep 12. pii: canres.0440.2016.
    PubMed     Text format     Abstract available


    August 2016
  67. ZHANG L, Wang J, Wang Y, Zhang Y, et al
    MNX1 is oncogenically upregulated in African-American prostate cancer.
    Cancer Res. 2016 Aug 30. pii: canres.0087.2016.
    PubMed     Text format     Abstract available


  68. WANG Y, Dehigaspitiya DC, Levine PM, Profit AA, et al
    Multivalent peptoid conjugates suppress enzalutamide-resistant prostate cancer cellular proliferation.
    Cancer Res. 2016 Aug 3. pii: canres.0385.2016.
    PubMed     Text format     Abstract available


  69. TSAI CH, Tzeng SF, Chao TK, Tsai CY, et al
    Metastatic progression of prostate cancer is mediated by autonomous binding of galectin-4-O-glycan to cancer cells.
    Cancer Res. 2016 Aug 2. pii: canres.0641.2016.
    PubMed     Text format     Abstract available


    July 2016
  70. LU H, Wang T, Li J, Fedele C, et al
    alphavbeta6 Integrin Promotes Castrate-Resistant Prostate Cancer Through JNK1-Mediated Activation of Androgen Receptor.
    Cancer Res. 2016 Jul 22. pii: canres.0543.2016.
    PubMed     Text format     Abstract available


    June 2016
  71. STOPSACK KH, Gerke TA, Sinnott JA, Penney KL, et al
    Cholesterol metabolism and prostate cancer lethality.
    Cancer Res. 2016 Jun 20. pii: canres.0903.2016.
    PubMed     Text format     Abstract available


  72. YOU S, Knudsen BS, Erho N, Alshalalfa M, et al
    Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome.
    Cancer Res. 2016 Jun 14. pii: canres.0902.2016.
    PubMed     Text format     Abstract available


    May 2016
  73. SHEIKH NA, Cham J, Zhang L, DeVries T, et al
    Clonotypic Diversification of Intratumoral T Cells Following Sipuleucel-T Treatment in Prostate Cancer Subjects.
    Cancer Res. 2016 May 23. pii: canres.3173.2015.
    PubMed     Text format     Abstract available


  74. SATO S, Katsushima K, Shinjo K, Hatanaka A, et al
    Histone deacetylase inhibition in prostate cancer triggers miR-320-mediated suppression of the androgen receptor.
    Cancer Res. 2016 May 23. pii: canres.3339.2015.
    PubMed     Text format     Abstract available


  75. ALBINO D, Civenni G, Dallavalle C, Roos M, et al
    Activation of the Lin28/let7 axis by loss of ESE3/EHF promotes a tumorigenic and stem-like phenotype in prostate cancer.
    Cancer Res. 2016 May 2. pii: canres.2665.2015.
    PubMed     Text format     Abstract available


  76. FERRALDESCHI R, Welti J, Powers MV, Yuan W, et al
    Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.
    Cancer Res. 2016;76:2731-2742.
    PubMed     Text format     Abstract available


    April 2016
  77. PASERO C, Gravis G, Guerin M, Granjeaud S, et al
    Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity.
    Cancer Res. 2016;76:2153-65.
    PubMed     Text format     Abstract available


  78. YU X, Wang H, Li X, Guo C, et al
    Activation of the MDA-5-IPS-1 Viral Sensing Pathway Induces Cancer Cell Death and Type I IFN-Dependent Antitumor Immunity.
    Cancer Res. 2016;76:2166-76.
    PubMed     Text format     Abstract available


  79. LINDQUIST KJ, Paris PL, Hoffmann TJ, Cardin NJ, et al
    Mutational Landscape of Aggressive Prostate Tumors in African American Men.
    Cancer Res. 2016;76:1860-8.
    PubMed     Text format     Abstract available


    March 2016
  80. PEITZSCH C, Cojoc M, Hein L, Kurth I, et al
    An epigenetic reprogramming strategy to re-sensitize radioresistant prostate cancer cells.
    Cancer Res. 2016 Mar 16. pii: canres.2116.2015.
    PubMed     Text format     Abstract available


  81. PRUEITT RL, Wallace TA, Glynn SA, Yi M, et al
    An Immune-Inflammation Gene Expression Signature in Prostate Tumors of Smokers.
    Cancer Res. 2016;76:1055-65.
    PubMed     Text format     Abstract available


  82. BILIR B, Osunkoya AO, Wiles WG 4th, Sannigrahi S, et al
    SOX4 Is Essential for Prostate Tumorigenesis Initiated by PTEN Ablation.
    Cancer Res. 2016;76:1112-21.
    PubMed     Text format     Abstract available


  83. ARGYROS O, Karampelas T, Asvos X, Varela A, et al
    Peptide-Drug Conjugate GnRH-Sunitinib Targets Angiogenesis Selectively at the Site of Action to Inhibit Tumor Growth.
    Cancer Res. 2016;76:1181-92.
    PubMed     Text format     Abstract available


    February 2016
  84. MIFTAKHOVA R, Hedblom A, Semenas J, Robinson BD, et al
    Cyclin A1 and P450 aromatase promote metastatic homing and growth of stem-like prostate cancer cells in the bone marrow.
    Cancer Res. 2016 Feb 26. pii: canres.2340.2015.
    PubMed     Text format     Abstract available


  85. TRAVIS RC, Appleby PN, Martin RM, Holly JM, et al
    A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk.
    Cancer Res. 2016 Feb 26. pii: canres.1551.2015.
    PubMed     Text format     Abstract available


  86. LINN DE, Penney KL, Bronson RT, Mucci LA, et al
    Deletion of interstitial genes between TMPRSS2 and ERG promotes prostate cancer progression.
    Cancer Res. 2016 Feb 15. pii: canres.1911.2015.
    PubMed     Text format     Abstract available


  87. NAKAJIMA K, Kho DH, Yanagawa T, Harazono Y, et al
    Galectin-3 cleavage alters bone remodeling: Different outcomes in breast and prostate cancer skeletal metastasis.
    Cancer Res. 2016 Feb 2. pii: canres.1793.2015.
    PubMed     Text format     Abstract available


    January 2016
  88. YAN J, Ojo D, Kapoor A, Lin X, et al
    Neural cell adhesion protein CNTN1 promotes the metastatic progression of prostate cancer.
    Cancer Res. 2016 Jan 21. pii: canres.1898.2015.
    PubMed     Text format     Abstract available


  89. NELSON WG
    Commentary on Huggins and Hodges: "Studies on Prostatic Cancer".
    Cancer Res. 2016;76:186-7.
    PubMed     Text format    


  90. LI N, Dhar SS, Chen TY, Kan PY, et al
    JARID1D is a suppressor and prognostic marker of prostate cancer invasion and metastasis.
    Cancer Res. 2016 Jan 8. pii: canres.0906.2015.
    PubMed     Text format     Abstract available


    December 2015
  91. MARTIN SK, Pu H, Penticuff JC, Cao Z, et al
    Multinucleation and mesenchymal-to-epithelial transition alleviate resistance to combined cabazitaxel and antiandrogen therapy in advanced prostate cancer.
    Cancer Res. 2015 Dec 8. pii: canres.2078.2015.
    PubMed     Text format     Abstract available


    November 2015
  92. CASIMIRO MC, Di Sante G, Ju X, Li Z, et al
    Cyclin D1 promotes androgen-dependent DNA damage repair in prostate cancer cells.
    Cancer Res. 2015 Nov 18. pii: canres.0999.2015.
    PubMed     Text format     Abstract available


  93. SHI XB, Ma A, Xue L, Li M, et al
    miR-124 and androgen receptor signaling inhibitors repress prostate cancer growth by downregulating androgen receptor splice variants, EZH2 and Src.
    Cancer Res. 2015 Nov 16. pii: canres.0795.2014.
    PubMed     Text format     Abstract available


  94. TA HQ, Ivey ML, Frierson HF Jr, Conaway MR, et al
    Checkpoint Kinase 2 Negatively Regulates Androgen Sensitivity and Prostate Cancer Cell Growth.
    Cancer Res. 2015.
    PubMed     Text format     Abstract available


  95. SPRATT DE, Evans MJ, Davis BJ, Doran MG, et al
    Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation.
    Cancer Res. 2015;75:4688-96.
    PubMed     Text format     Abstract available


    October 2015
  96. HURLEY PJ, Hughes RM, Simons BW, Huang J, et al
    Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.
    Cancer Res. 2015;75:4322-34.
    PubMed     Text format     Abstract available


  97. WANG M, Kimbrell HZ, Sholl AB, Tulman DB, et al
    High-Resolution Rapid Diagnostic Imaging of Whole Prostate Biopsies Using Video-Rate Fluorescence Structured Illumination Microscopy.
    Cancer Res. 2015;75:4032-41.
    PubMed     Text format     Abstract available


    September 2015
  98. BERNARDO MM, Kaplun A, Dzinic SH, Li X, et al
    Maspin Expression in Prostate Tumor Cells Averts Stemness and Stratifies Drug Sensitivity.
    Cancer Res. 2015;75:3970-9.
    PubMed     Text format     Abstract available


  99. XU D, Zhan Y, Qi Y, Cao B, et al
    Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes.
    Cancer Res. 2015;75:3663-71.
    PubMed     Text format     Abstract available


    April 2015
  100. BROWN M, Chinnaiyan A, Farsetti A, Livingston DM, et al
    26th Pezcoller symposium: cancers driven by hormones.
    Cancer Res. 2015;75:1177-80.
    PubMed     Text format     Abstract available


  101. FOX JL, Storey A
    BMX Negatively Regulates BAK Function, Thereby Increasing Apoptotic Resistance to Chemotherapeutic Drugs.
    Cancer Res. 2015;75:1345-55.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: